<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75472">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813344</url>
  </required_header>
  <id_info>
    <org_study_id>LBL-CISL-1</org_study_id>
    <nct_id>NCT01813344</nct_id>
  </id_info>
  <brief_title>Hyper-CVAD Treatment in Lymphoblastic Lymphoma</brief_title>
  <acronym>LBL-CISL-1</acronym>
  <official_title>The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens
      for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with
      high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment
      outcome of hyper-CVAD in LBL has reported only in small number of patients from single
      institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based
      treatment in LBL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD
      regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment.
      After achievement of response, patients either underwent hematopoietic stem cell
      transplantation (HSCT) or consolidation with hyper-CVAD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3-year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoblastic Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult lymphoblast lymphoma patients treated with hyper-CVAD regimen in Korea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18 at diagnosis

          -  Pathologically proven lymphoblastic lymphoma

        Exclusion Criteria:

          -  proven HIV infection

          -  pretreatment with other regimens
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seong Hyun Jeong, MD</last_name>
    <phone>+82-31-219-5989</phone>
    <email>seonghyunmd@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ajou Universtiy School of Medicine</name>
      <address>
        <city>Suwon</city>
        <state>Kyeonggi</state>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geum Sook Jeong, MS</last_name>
      <phone>+82-31-219-5990</phone>
      <email>geumsook@ajou.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 14, 2013</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Seong Hyun Jeong</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Adult lymphoblastic lymphoma</keyword>
  <keyword>Hyper-CVAD</keyword>
  <keyword>first-line treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
